Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Tsai-Shen YANG"'
Autor:
Chia-Hsun Hsieh, Cheng-lung Hsu, Cheng-Hsu Wang, Chaung-Chi Liaw, Jen-Shi Chen, Hsien-Kun Chang, Tsai-Shen Yang, John Wen-Chen Chang, Yung-Chang Lin, Chi-Ting Liau, Ngan-Ming Tsang, Joseph Tung-Chieh Chang, Shu-Hang Ng, Hung-Ming Wang
Publikováno v:
Biomedical Journal, Vol 36, Iss 5, Pp 229-236 (2013)
Background: This prospective phase II clinical trial evaluated the efficacy and toxicity of cisplatin, oral tegafur-uracil, leucovorin, and mitomycin C in patients with recurrent or metastatic nasopharyngeal carcinoma. Methods: Patients with histolo
Externí odkaz:
https://doaj.org/article/5a18c3115cf74cccbe55314110dd1eed
Autor:
Yaqi Zhang, Ying Cheng, Zhixiang Jian, Tsai Shen Yang, Jun Liang, Yuxian Bai, Yan Sun, Kun Ming Rau, Jia Fan, Lin Shen, Jianfeng Li, Lijian Liang, Gang Wu, Shukui Qin, Houjie Liang
Publikováno v:
The Oncologist. 19:1169-1178
Background.The EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) compared with doxorubicin alone in terms of overall survival (OS), progression-free survival (PFS), and safety in patients with advan
Autor:
MOK, Tony1 mok206551@cuhk.edu.hk, Tsai-Shen YANG2, Yee CHAO3, Cheng-Hsu WANG4, Mei-Ching LIU5, Yoon Koo KANG6, Won Ki KANG7, Jun Suk KIM8, Yajie WANG9, Thomas LEUNG1
Publikováno v:
Asia Pacific Journal of Clinical Oncology. Jun2009, Vol. 5 Issue 2, p95-100. 6p. 2 Charts, 1 Graph.
Autor:
Jee Hyun Lee, Yan Sun, Won Ki Kang, Tsai-Shen Yang, Shukui Qin, Jia Fan, Yee Chao, Yu Zhou, Ho Yeong Lim, Sumitra Thongprasert, Yuxian Bai, Vajarabhongsa Bhudhisawasdi
Publikováno v:
Journal of Clinical Oncology. 31:3501-3508
Purpose To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin.
Autor:
Chiun Hsu, Tzeon Jye Chiou, Jennifer Sandoval-Tan, Yu-Yun Shao, Kate Jin, Chia-Tung Shun, Ann-Lii Cheng, Chih-Hung Hsu, Wu Chou Su, Yoon-Koo Kang, Tsai Shen Yang
Publikováno v:
Oncology. 85:44-52
Objectives: The bevacizumab/erlotinib combination was reported with high clinical activity for advanced hepatocellular carcinoma (HCC) by a phase II study conducted in the USA. This multicenter study across several Asian countries was to evaluate the
Autor:
Yajie Wang, Jun Suk Kim, Cheng Hsu Wang, Yee Chao, Yoon-Koo Kang, Mei Ching Liu, Tsai Shen Yang, Won Ki Kang, Tony Mok, Thomas W. Leung
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 5:95-100
Aim: Hepatocellular carcinoma (HCC) is one of the most commonly fatal malignancies in Asia but treatment options are limited. Methods: This multinational, nonrandomized phase II trial using the combination of irinotecan (Campto or CPT-11) and capecit
Autor:
Yongyu Wang, Masatoshi Kudo, Ana-Marie Rodriguez, Ronnie Tung-Ping Poon, Binaifer Balsara, Ho Yeong Lim, Sumitra Thongprasert, Ann-Lii Cheng, Wattana Sukeepaisarnjaroen, Masafumi Ikeda, Yi Zhang, Yee Chao, Hongming Pan, Stephen L. Chan, Tsai-Shen Yang, Kazushi Numata, Yoon-Koo Kang, Guohong Han, Cheng-Chung Wu, Yong Zhang
Publikováno v:
Hepatology (Baltimore, Md.). 64(3)
Angiogenesis inhibition by the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor sorafenib provides survival benefit in hepatocellular carcinoma (HCC); however, angiogenic escape from so
Autor:
Jy-Ming Chiang, Tsai-Shen Yang, Jinn-Shium Chen, Chung-Rong Changchien, Reiping Tang, Chien-Yu Yeh, Pau-Shiu Hsieh
Publikováno v:
Anti-Cancer Drugs. 14:145-151
The primary objective of this study was to determine the maximum tolerable dose (MTD) and dose-limiting toxicity (DLT) for bolus 5-fluorouracil (5-FU) administered on a biweekly schedule and in combination with fixed doses of leucovorin (LV) and oxal
Publikováno v:
Japanese Journal of Clinical Oncology. 32:352-357
Background: The purpose of this study was to determine the efficacy and toxicity of uracil/ ftorafur (UFT) plus oral leucovorin (LV) as first-line chemotherapy for patients with metastatic colorectal cancer and salvage chemotherapy with weekly high-d
Autor:
Jy-Ming Chiang, Kuan-Cheng Hsu, Chung-Rong Changchien, Reiping Tang, Tsai-Shen Yang, Jinn-Shium Chen, Jeng-Yi Wang
Publikováno v:
Cancer. 85:1925-1930
BACKGROUND Reports of in vitro experiments in colorectal carcinoma cells suggest that prolonged cellular exposure to 5-fluorouracil (5-FU) combined with relatively low concentrations of leucovorin (LV) provides optimal enhancement of 5-FU efficacy. I